SWOG clinical trial number
SWOG-8391

Intergroup Adult Adjuvant Soft Tissue Sarcoma Protocol #2, A Randomized Trial of Adjuvant Doxorubicin vs. Standard Therapy (A Delay of Chemotherapy Until the Time of Possible Relapse)

Closed
Phase
Published
Abbreviated Title
Intergroup Adult Adjuvant Soft Tissue Sarcoma Protocol #2, A Randomized Trial of Adjuvant Doxorubicin vs. Standard Therapy (A Delay of Chemotherapy Until the Time of Possible Relapse)
Activated
02/18/1983
Closed
06/15/1986

Publication Information Expand/Collapse

1991

Pooled results from three randomized adjuvant studies of doxorubicin versus observation in soft tissue sarcoma: 10 year results and review of the literature.

K Antman;L Ryan;E Borden;WC Wood;HL Lerner;JM Corson;R Carey;H Sult;S Balcerzak;A Elias;L Baker Adjuvant Therapy of Cancer, SE Salmon (ed.)W.B. Saunders Co VI:529-542

1990

Pooled results from three randomized adjuvant studies of doxorubicin versus observation in soft tissue sarcoma: 10 year results.

K Antman;L Ryan;E Borden;W Wood;H Lerner;J Corson;R Carey;H Suit;S Balcerzak;M Sherman;L Baker ASCO 9:311(#1204)

1987

A preliminary analysis of a randomized intergroup (SWOG, ECOG< CALGB, NCOG) trial of adjuvant doxorubicin for soft tissue sarcomas.

K Antman;D Amato;M Pilepich;H Lerner;S Balcerzak;E Borden;L Baker Adjuvant Therapy of Cancer V:725-734

A randomized intergroup trial of adjuvant doxorubicin (DOX) for soft tissue sarcomas (STS): Lack of apparent difference between treatment groups.

K Antman;D Amato;M Pilepich;H Lerner;S Balcerzak;E Borden;L Baker ASCO 6:134(525)